Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib

Hyo Jung Cho
* ORCID logo ,
Ji Eun Han
ORCID logo ,
Jisu Kim
,
Jae Youn Cheong
ORCID logo ,
Soon Sun Kim
ORCID logo ,
Sun Gyo Lim
,
Min Jae Yang
ORCID logo ,
Choong-Kyun Noh
ORCID logo ,
Gil Ho Lee
ORCID logo ,
Jung Woo Eun
,
Bumhee Park
Version 1 : Received: 14 December 2023 / Approved: 15 December 2023 / Online: 15 December 2023 (12:14:20 CET)

A peer-reviewed article of this Preprint also exists.

Han, J.E.; Kim, J.; Cheong, J.Y.; Kim, S.S.; Lim, S.G.; Yang, M.J.; Noh, C.-K.; Lee, G.H.; Eun, J.W.; Park, B.; Cho, H.J. The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib. Cancers 2024, 16, 249. Han, J.E.; Kim, J.; Cheong, J.Y.; Kim, S.S.; Lim, S.G.; Yang, M.J.; Noh, C.-K.; Lee, G.H.; Eun, J.W.; Park, B.; Cho, H.J. The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib. Cancers 2024, 16, 249.

Abstract

We aimed to evaluate the survival benefits of coadministering statins and multityrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC). Data from the Health Insurance Review and Assessment Service in Korea (2010–2020) were utilized. Statin use (≥28 cumulative defined daily doses) was analyzed, with 1,534 statin users matched to 6,136 non-users (1:4 ratio) using propensity scores. Primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS). Statin use significantly improved OS (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.72–0.82, P<0.001) and PFS (HR 0.78, 95% CI 0.74–0.84, P<0.001). Continuous or post-TKI statin users had better OS, while discontinuation after TKI use led to poorer OS. Both lipophilic and hydrophilic statins improved OS and PFS, particularly with ≥730 cumulative defined daily doses. In conclusion, combining statins and TKIs in patients with advanced HCC yielded significant survival benefits, influenced by statin dosage and duration. Continuous statin administration post-TKI treatment is crucial for improving outcomes in patients with HCC.

Keywords

statin; multityrosine kinase inhibitor; sorafenib resistance; hepatocellular carcinoma; lipophilic statin; hydrophilic statin

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.